Table VII.
Characteristics | Drug survival rates [percentage (CI)] for a specific drug∗ |
Median drug survival (CI) | ||
---|---|---|---|---|
3 months | 6 months | 12 months | ||
Patient characteristics | ||||
Sex | ||||
Male | 88.2 (83.1-91.8) | 74.2 (67.6-79.6) | 56.0 (48.4-62.9) | 14.1 (11.5-20-3) |
Female | 83.0 (75.5-88.3) | 74.1 (65.7-80.8) | 59.1 (49.8-67.3) | 16.8 (12.0-27.5) |
Arthritis | ||||
No | 88.3 (83.6-91.7) | 75.0 (69.0-80.1) | 56.4 (49.4-62.8) | 14.8 (11.9-17.4) |
Yes | 79.2 (69.1-86.4) | 74.0 (63.2-82.1) | 61.9 (49.9-71.8) | 21.4 (11.8-31-1) |
Age at therapy start | ||||
≥40 years | 87.8 (83.2-91.3) | 76.7 (70.9-81.6) | 62.6 (55.8-68.6) | 18.2 (14.5-25.2) |
<40 years | 81.9 (72.8-88.2) | 67.4 (56.9-75.9) | 44.0 (3.3-54.2) | 9.9 (7.1-15.8) |
BMI | ||||
<30 | 78.4 (64.4-87.4) | 66.3 (51.5-77.5) | 55.9 (41.0-68.4) | 14.5 (7.1-23.4) |
≥30 | 81.8 (58.5-92.8) | 77.0 (53.2-89.7) | 66.3 (41.8-82.5) | 21.9 (6.5-NA) |
Biologic naïvety | ||||
No | 76.2 (67.6-82.8) | 65.5 (56.2-73.3) | 52.5 (42.8-61.4) | 13.1 (7.3-16.8) |
Yes | 91.4 (86.9-94.3) | 78.6 (72.5-83.5) | 59.6 (52.3-66.2) | 17.4 (12.9-25.2) |
Disease characteristics | ||||
Palmar and/or plantar involvement | ||||
No | 86.4 (82.1-89.7) | 74.3 (68.9-78.8) | 57.5 (51.3-63.1) | 15.7 (12.8-19.1) |
Yes | 82.5 (66.7-91.3) | 71.2 (53.9-83.0) | 54.0 (35.6-69.2) | 15.0 (8.1-35.9) |
Scalp involvement | ||||
No | 86.9 (82.4-90.4) | 75.0 (69.4-79.8) | 57.4 (50.9-63.4) | 15.8 (12.4-22.8) |
Yes | 83.1 (72.2-90.1) | 70.7 (58.2-80.0) | 56.6 (43.4-67.9) | 15.1 (7.2-21.8) |
Nail involvement | ||||
No | 86.5 (81.8-90.1) | 74.0 (68.2-79.0) | 58.8 (52.2-64.8) | 15.9 (13.1-21.9) |
Yes | 85.2 (75.9-91.1) | 74.7 (63.8-82.8) | 52.1 (39.5-63.2) | 12.9 (9.5-21.8) |
Inverse involvement | ||||
No | 87.1 (82.9-90.4) | 74.7 (69.4-79.2) | 57.6 (51.4-63.2) | 15.8 (12.9-21.4) |
Yes | 78.0 (60.8-88.4) | 69.1 (51.1-81.6) | 54.7 (35.9-70.1) | 15.7 (6.4-NA) |
Overall survival per drug | 86.2 (82.1-89.4) | 74.1 (69.1-78.5) | 57.3 (51.5-62.6) | 15.7 (12.8-20.3) |
CI, Confidence interval; NA, not applicable.
Percentages (confidence interval) of drug survival at 12 months (N = 367).